Artificial neural networks imitate learning processes and interactions between human neurons. 8 During the training phase, it gradually reduces the deviation of prediction by learning the relationships among inputs (variables) and outputs (prediction results) as well as relationships between the input variables. Finally, the ANN has the ability to predict the probability of BCR.
INTRODUCTION
Prostate-specific antigen (PSA) is a widely accepted screening parameter for early detection of prostate cancer (PCa). Treatment of localized PCa is often performed by radical surgery such as laparoscopic radical prostatectomy (LRP). 1 The PSA value in most patients will drop to zero within 2 months after LRP. A consecutive increase of serum PSA up to 0.1 or 0.2 ng ml −1 is defined as biochemical recurrence (BCR). 2 BCR is considered a predictor of clinical recurrence and metastasis of PCa. 3, 4 Therefore, early identification and treatment of BCR is important to improve the long-term survival.
Presently, Gleason Score (GS), preoperative PSA, and pathological stages (pTs) are the main parameters used to predict the risk of BCR. 5 For higher accuracy and specificity; multivariate logistic regression (LR) models such as nomograms 6 have been used to improve prediction. Most applications of LR in BCR prediction are available with standard nomograms, but there are only few artificial neural networks (ANNs) available for BCR prediction 7 and none is freely available online. Further, there are no available models that calculate the individual BCR free probability at multiple time-points after operation especially after different time periods without BCR.
ORIGINAL ARTICLE
Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score 18 From a practical point of view, there is an urgent need for tools that provide information on recurrence-free survival (FS) at distinct time points after radical prostatectomy taking into account the already elapsed recurrence-free interval.
MATERIALS AND METHODS

Study population
Between 1999 and 2007, 1897 PCa patients underwent LRP at our institution. Among them, 322 patients were lost to follow-up or had to be eliminated due to neo-adjuvant hormonal therapy or largely incomplete datasets. The remaining 1575 patients were divided into two groups: 1300 patients (82.5%) with no evidence of BCR (nonBCR) and 275 patients (17.5%) with BCR (BCR group). The median follow-up period was 82.1 months (range from 0.2 to 129.5).
Data collection
Biochemical recurrence was defined as serum PSA levels greater than 0.1 ng ml −1 at two consecutive time points. All preoperative blood samples were measured by Immulite® 2000 assays (Siemens Healthcare, Erlangen, Germany). Data collection included: age, PSA, free/total PSA (%fPSA), prostate weight, digital rectal examination (DRE) status, pT, 19 margin status (positive surgical margin [PSM] or negative surgical margin [NSM] ) and GS. 20 For the parameter distribution analysis, pTs of the prostatectomy specimens were classified into pT2, pT3/4; GS <7, GS =7, GS >7; PSM or NSM; positive DRE or negative DRE. PSA, margin status, pT and GS were used for ANN and LR analysis.
This study was conducted under a local Ethics Committee approved protocol and obeys Reporting of Diagnostic Accuracy guidelines.
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Statistical analysis
Artificial neural network and LR models were computed using the MATLAB-software and the Neural Network Toolbox (Mathworks, Natick, MA, USA). Each ANN (feed forward network with error back propagation) had three layers: input layer with four neurons, hidden layer with two neurons and output layer with one neuron representing the nonBCR probability. Follow-up data after LRP were collected every 6 months and respectively added into the separate models. Every 6 months separate models (ANN and LR) were calculated with those patients still not having a BCR at this time-point (those with a BCR earlier were excluded) and those who were not censored. For all models, internal validation was performed with the leave one out method.
Statistical analysis was performed using SPSS 19.0 (IBM, Chicago, IL, USA) and MedCalc 12.4.0 (MedCalc Software, Mariakerke, Belgium) to compare all variables using receiver operating characteristic (ROC) analyses regarding sensitivity, specificity and areas under ROC curve (AUC). The comparison of ROC curves were performed with the method of Delong and the comparison of prediction results were conducted using Mann-Whitney U test for continuous variables and Fisher's exact test for ordinal variables. Differences were considered statistically significant if P < 0.05. Table 1 displays the patient characteristics as well as the distribution of clinico-patholological parameters of the BCR and nonBCR group. There were no relevant differences between the two groups for age (P = 0.37), PSA (P = 0.12), %fPSA (P = 0.26), prostate volume (P = 0.33), and PSA density (P = 0.11). In contrast, the pathological GS, margin status, and pT were different between the BCR and nonBCR group except for GS =7 (P = 0.12), as shown in Table 1 .
RESULTS
Baseline characteristics
Receiver operating characteristic analysis of selected parameters
Specificities of the BCR prediction results computed by ANN and LR models with the PSA, margin status, pT, and GS directly after LRP were the highest at both sensitivity cutoffs of 90% and 95%, as shown in Table 2 . GS and PSA showed lower specificities and lower AUCs than ANN and LR. Figure 1 clearly shows the larger AUCs of the two models compared with GS and PSA alone. Table 3 displays the pairwise comparison of all parameters. While ANN and LR were not different (P = 0.39), ANN and LR predicted BCR better than PSA or Biochemical recurrence-free survival curves Figure 2 displays probabilities for BCR-FS up to 2.5, 5, and 7.5 years after LRP for different categories of GS and ANN outputs. PCa patients with GS <7 always have the highest probability for BCR-FS compared with patients with GS =7 or GS >7 (Figure 2a-2c) .
In predicting BCR-FS, ANN, and LR perform similarly (LR data not shown). To allow better differentiation of patients who more urgently may need adjuvant radiation (and hormonal treatment) we subdivided all patients using the continuous ANN output values and separated them into two groups below and above the median. This median output was calculated from the 1575 ANN output values according to the prevalence of nonBCR. Figure 2d-2f shows the difference between patients above and below the median ANN output values with up to 2.5, 5, and 7.5 years of follow-up.
Analysis of individual ANN output values had no benefit in patients with a GS <7 PCa but it improved the prediction for all patients with GS ≥7. Of all 1026 PCa patients with GS ≥7, 235 (23%) had a BCR ( 22 ANN is also used to predict the outcome of repeat prostate biopsies, 23 and furthermore, to predict the risk of lymph node metastasis in PCa patients. 24 However, ANN applications to predict BCR are rare. 7, 10 Our data on BCR prediction show that ANN and LR models including the parameters PSA, margin status, pT and GS, can correctly simulate and reflect interactions between variables in the training set. The models improve the prediction better than any single variable and thus estimate BCR more accurately for each individual patient with PCa. 25 Some studies have verified that ANN models have the ability to improve prognosis prediction for PCa patients after prostatectomy. 7, 10, [26] [27] [28] [29] These data have been summarized in Table 5 . One of the first studies in 1994 demonstrated 87% accuracy. 26 Among all available studies to date, the results by Tewari et al. 7 showed the best AUC with 0.83; however, their accuracy was somewhat lower than in the present study and in other studies. Potter et al. 26 gained similar AUCs of 0.71, 0.74, 0.74 using different input parameters, but the specificity was relatively lower than in our present study. However, despite large differences in sensitivity and specificity levels there are relatively small accuracy ranges (70%-87%) and AUCs between 0.71 and 0.83 for all studies. This demonstrates that the parameters that were used do not allow a better prediction of BCR. Interestingly, PSA has been thought to improve prediction of BCR following PCa diagnosis; 30 however in our study, %fPSA did not improve prognosis. The median values were not different between the non-BCR and BCR group (10.7 vs 9.2%; P = 0.26) ( Table 1 ).
An important finding was the additional benefit of our ANN for patients with aggressive PCa (GS ≥7). Among 1026 patients, 235 had a BCR (23%). Patients with a low ANN value (below the chosen cutoff) had only 16.5% of the 768 BCR ( Table 4 ). But if patients had an ANN value above the cutoff, 41.9% showed BCR. This rate is almost doubled in comparison to the 23% without considering the ANN output value and almost tripled in comparison to the group below the cutoff. However, analysis of individual ANN output values had no benefit in patients with GS <7 PCa, where only 40 patients had a BCR.
When further analyzing the 260 patients with highly aggressive PCa and a GS > 7, the overall BCR rate of 43.5% (113 of 260). This rate dropped when the ANN value was below the cutoff. Only 28 of 96 patients (29.2%) had a BCR. In contrast, those patients with aggressive PCa and high ANN values had a >50% likelihood to have a BCR (51.8%; 85 of 164). This individual risk estimation could support further treatment, especially in patients with high GS and high ANN values compared with lower risk patients.
Uniquely, our calculated models at every 6 months following surgery can provide the individual BCR free probability at individual time-points after a BCR free period. For example, as shown in Figure 2b , a patient with a GS of 7 and a recurrence free survival of 3 years after LRP only has an 8% likelihood of a BCR up to 5 years, and 14% up to 7.5 years (Figure 2c) . Without considering the three BCR free years, the estimated BCR risk would be ~22%. This allows for a more optimistic prognosis in comparison to those values calculating risk only immediately after prostatectomy. A limitation of this study is the availability of only internal validation results for all models. However, our aim was to demonstrate the possibility of improving individual BCR estimation at any point after LRP. Another limitation was the decreased available patient data with increased follow-up time.
Nevertheless, patient's age, PSA, and GS were found to play a distinct role in PCa prognosis. 3, 31, 32 Currently, those prediction parameters and the ANN output value best predict a PCa recurrence. Further, with our ANN models, this prediction can be made for an individual time point after LRP and with patients who have BCR free time-points. Other parameters such as %fPSA or the margin status did not contribute as speculated before. The %fPSA performs well in PCa diagnosis, but is less competitive in the prognosis of PCa or BCR, therefore it is not used in our models. 
CONCLUSION
The predictive ability of our ANN and LR models is better than single standard parameters GS and PSA. Our models for individual BCR free probability at individual time-points after a BCR free period offer an individual BCR prediction. By combining the GS and ANN output value, a BCR prediction is more accurate and may lead to a more accurate application of adjuvant therapy after prostatectomy especially in high-risk patients with GS ≥7.
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